Loading stock data…
Theravance Biopharma (TBPH)
$17.06-0.57 (-3.23%)
After Hours$17.06+0.00 (+0.00%)· Last close Jun 29
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Theravance Biopharma, Inc. in the Healthcare sector is trading at $17.06 with a market capitalization of $849M. Wall Street consensus targets $17.40 (5 analysts), implying a +2.0% move over the next 12 months. The stock is currently 19% below its 52-week high of $21.03, remaining 1.9% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.70M↓ | $45.89M↑ | $19.99M↓ | $26.20M↑ | $15.39M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.85M↓ | $20.01M↑ | -$6.46M↓ | -$2.73M↑ | -$14.43M |
| Net Income | -$4.93M↓ | $61.02M↑ | $3.62M↓ | $54.84M↑ | -$13.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary dise...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$848.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
39.42%
Volume
Today's trading volume
3.10M
Recent News
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders
Theravance Biopharma shareholders will receive a contingent value right (CVR) under which they will get 80% of the net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years.
Zymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.
Shares of Theravance Biopharma were sliding in premarket trading Monday after larger biotech Zymeworks agreed to acquire the company for roughly $929 million. Under the terms of the deal, Zymeworks will pay $17 a share in cash for Theravance, representing 3.6% discount to Friday’s closing price of $17.63 but a 22% premium to its closing price on March 3, after the company reported a late-stage trial failure for its drug candidate, ampreloxetine. Theravance stock slipped 2.7% to $17.14 in Monday’s premarket session, while Zymeworks fell 5.6%.
Zymeworks to Acquire Theravance Biopharma in $929 Million Deal
Zymeworks (ZYME) has signed a definitive agreement to acquire Theravance Biopharma (TBPH) for $17 pe
Theravance, after clinical setbacks, agrees to $929M buyout
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.